Immuno-Oncology 2014: Information for Media Representatives
After a very successful first edition in 2013 and in light of the growing importance of immune therapies in oncology, the second “ESMO Symposium on Immuno-oncology – Advances in cancer immunotherapy: from vaccines to antibodies and cell therapies” is expected to welcome over 400 participants from all over the world: medical oncologists from all areas of specialisation as well as other oncology specialists interested in learning the basics of immunotherapies, hearing the latest research results, understanding how to deal with treatment options and toxicities and interpret the new wave of data.
Abstracts are available here.
ESMO welcomes media interested in obtaining information and reporting on cancer issues.
Registration is free to bona fide journalists on presentation of a letter of assignment and a valid press card.
Media representatives are required to observe and abide by the ESMO Media Policy which applies to all ESMO events.
To register for the event, please fill out the Complimentary Media Registration Form.
Media registration in advance is strongly recommended although on-site registration will still be possible.
Please contact the ESMO Press Office for any additional question.
ESMO Press Office
|24 Nov 2014||Immuno-Oncology 2014 Press Release: High-Dose Interleukin-2 Effective in mRCC Pre-Treated With VEGF-Targeted Therapies||Genitourinary cancers - Cancer Immunology and Immunotherapy|
|21 Nov 2014||Immuno-Oncology 2014 Press Release: Immune Checkpoint Inhibitors May Work in Brain Cancer||Central nervous system malignancies - Cancer Immunology and Immunotherapy|
|21 Nov 2014||Immuno-Oncology 2014 Press Release: Possibilities for Personalised Vaccines Revealed at ESMO Symposium||Personalised medicine - Cancer Immunology and Immunotherapy|
|20 Nov 2014||Immuno-Oncology 2014 Press Release: Immunotherapy Set to Revolutionise Cancer Treatment||Cancer Immunology and Immunotherapy|